scholarly journals 3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity

ChemMedChem ◽  
2016 ◽  
Vol 11 (16) ◽  
pp. 1700-1704 ◽  
Author(s):  
Loana Musso ◽  
Raffaella Cincinelli ◽  
Valentina Zuco ◽  
Michelandrea De Cesare ◽  
Franco Zunino ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
New Class

Synthesis and Antitumor Activity of a New Class of Pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone Analogs of Pyrrolo[1,4][2,1-c]benzodiazepines

1994 ◽  
Vol 37 (25) ◽  
pp. 4329-4337 ◽  
Author(s):  
Pier Giovanni Baraldi ◽  
Alberto Leoni ◽  
Barbara Cacciari ◽  
Stefano Manfredini ◽  
Daniele Simoni ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
New Class

scholarly journals Antitumor Activity of 7-Aminocarboxycoumarin Derivatives, a New Class of Potent Inhibitors of Lactate Influx but Not Efflux

2014 ◽  
Vol 13 (6) ◽  
pp. 1410-1418 ◽  
Author(s):  
Nihed Draoui ◽  
Olivier Schicke ◽  
Emmanuel Seront ◽  
Caroline Bouzin ◽  
Pierre Sonveaux ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
New Class

A new class of nitrosoureas. 4. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas

1982 ◽  
Vol 25 (4) ◽  
pp. 441-446 ◽  
Author(s):  
Kenji Tsujihara ◽  
Masakatsu Ozeki ◽  
Tamio Morikawa ◽  
Masatoshi Kawamori ◽  
Yukio Akaike ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
New Class ◽  
Derivatives Of

A New Class of Symmetric Bisbenzimidazole-Based DNA Minor Groove-Binding Agents Showing Antitumor Activity

2001 ◽  
Vol 44 (2) ◽  
pp. 138-144 ◽  
Author(s):  
John Mann ◽  
Anne Baron ◽  
Yaw Opoku-Boahen ◽  
Eric Johansson ◽  
Gary Parkinson ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Minor Groove ◽  
Minor Groove Binding ◽  
Groove Binding ◽  
Dna Minor Groove ◽  
New Class ◽  
Binding Agents

Capecitabine: Indications and Future Perspectives in the Treatment of Metastatic Colorectal and Breast Cancer

2001 ◽  
Vol 87 (6) ◽  
pp. 364-371 ◽  
Author(s):  
Antonino Cassata ◽  
Giuseppe Procopio ◽  
Massimiliano Alù ◽  
Leonardo Ferrari ◽  
Erminia Ferrario ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Antitumor Activity ◽  
Dihydropyrimidine Dehydrogenase ◽  
Continuous Intravenous Infusion ◽  
Future Perspectives ◽  
New Agents ◽  
New Class ◽  
Oral Tumor

Fluoropyrimidines remain the most important drugs in the treatment of breast and colorectal carcinoma, but response rates and survival time have been disappointing. Optimal administration is by continuous intravenous infusion, which makes it cumbersome to use and compromises patient independence. Recently, a number of new agents, including fluorouracil prodrugs and selective dihydropyrimidine dehydrogenase inhibitors, have been studied, with promising results. Capecitabine is the first in a new class of fluoropyrimidines. It is an oral, tumor-activated anticancer drug whose activity mimics that of continuously infused 5-fluorouracil. Capecitabine circumvents dihydropyrimidine dehydrogenase catabolism and appears to be at least as active against metastatic colorectal and breast cancer as conventionally administered intravenous 5-fluorouracil, with significantly less toxicity, an improved quality of life, and lesser cost. Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-containing regimes for advanced colorectal and breast cancer.

Solvent‐Free Synthesis and In Vitro Antitumor Activity of a New Class of ( Z )‐3‐Arylidene‐1 H ‐pyrano[3,4‐ b ]quinolin‐4(3 H )‐ones

2020 ◽  
Vol 5 (9) ◽  
pp. 2746-2752
Author(s):  
Yang Li ◽  
Bingyue Tang ◽  
Shiyu Dong ◽  
Wentao Gao ◽  
Wenting Jiang ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Solvent Free ◽  
New Class ◽  
Solvent Free Synthesis
Sign in / Sign up

Export Citation Format

Share Document